English (United States)

FLAME : first patient included in Luxembourg

reduce font Size enlarge font Size print content

Patients with chronic moderate to very server chronic obstructive pulmonary disease (COPD) are currently being recruited

Currently a 52-week treatment, phase IIIB, multi center, randomized study is being conducted to demonstrate that QVA149 (indacaterol maleate / glycopyrroniumbromide) is at least non inferior to Salmeterol/Fluticasone on the rate of exacerbations in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD). COPD is the name for a collection of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways disease. A COPD exacerbation means that there is a worsening of COPD symptoms.

The approximate total number of patients will be 3332. The study population will consist of male and female adults age 40 years and older, with a clinical diagnosis of COPD, a smoking history of at least 10 pack years and a documented history of at least 1 COPD exacerbation requiring systemic glucocorticosteroids and/or antibiotics in the previous 12 months.

The CHL hospital is one of the recruiting sites with the participation of the CIEC. Additional information on this trial is available on our website under following link https://www.luxclin.lu/Studies/Details/?c=STP2826DEE.

Reference: http://clinicaltrials.gov/ct2/show/NCT01782326?term=QVA+149A+2318&rank=1

Who should register?

Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.

Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.